COVID-19: Impact of and on Diabetes
Open Access
- 6 June 2020
- journal article
- review article
- Published by Springer Science and Business Media LLC in Diabetes Therapy
- Vol. 11 (7), 1429-1435
- https://doi.org/10.1007/s13300-020-00847-5
Abstract
Diabetes has been identified as a pre-existing health condition linked with worse outcomes following coronavirus disease 2019 infection. Here we explore the association between hyperglycaemia and more severe illness, the impact of the pandemic on diabetes service delivery, and the resultant opportunities for innovation.This publication has 35 references indexed in Scilit:
- Closed-Loop Insulin Delivery for Glycemic Control in Noncritical CareThe New England Journal of Medicine, 2018
- Infection and Malignancy Outweigh Cardiovascular Mortality in Kidney Transplant Recipients: Post Hoc Analysis of the FAVORIT TrialThe American Journal of Medicine, 2017
- Liraglutide attenuates lipopolysaccharide-induced acute lung injury in miceEuropean Journal of Pharmacology, 2016
- Anti-Inflammatory Effects of Metformin Irrespective of Diabetes StatusCirculation Research, 2016
- The Effect of Short-Term Hyperglycemia on the Innate Immune SystemThe American Journal of the Medical Sciences, 2016
- The Effect of Exogenous Glucose-Dependent Insulinotropic Polypeptide in Combination With Glucagon-Like Peptide-1 on Glycemia in the Critically IllDiabetes Care, 2013
- Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMCNature, 2013
- Feasibility of fully automated closed-loop glucose control using continuous subcutaneous glucose measurements in critical illness: a randomized controlled trialCritical Care, 2013
- Binding of SARS coronavirus to its receptor damages islets and causes acute diabetesActa Diabetologica, 2009
- Intensive Insulin Therapy Exerts Antiinflammatory Effects in Critically Ill Patients and Counteracts the Adverse Effect of Low Mannose-Binding Lectin LevelsJournal of Clinical Endocrinology & Metabolism, 2003